Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GC012F in Refractory Idiopathic Inflammatory Myopathy
NCT07086404Phase 1Recruiting
- Sponsor
- Daishi Tian
- Start
- Sep 2025
- Primary completion
- Sep 2027
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of GC012 in idiopathic inflammatory myopathy (IIM), sponsored by Daishi Tian. Primary endpoints: Dose-Limiting Toxicity at 28 days and Adverse Events at 96 weeks. Started Sep 2025; status: recruiting.
02
Drugs
GC012
03
Conditions
idiopathic inflammatory myopathy (IIM)
Beyond the preview
Go deeper on NCT07086404.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07086404.